Hydrocortisone plus fludrocortisone for adults with septic shock.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Septic shock is characterized by dysregulation of the host response to infection, with circulatory, cellular, and metabolic abnormalities. We hypothesized that therapy with hydrocortisone plus fludrocortisone or with drotrecogin alfa (activated), which can modulate the host response, would improve the clinical outcomes of patients with septic shock. METHODS: In this multicenter, double-blind, randomized trial with a 2-by-2 factorial design, we evaluated the effect of hydrocortisone-plus-fludrocortisone therapy, drotrecogin alfa (activated), the combination of the three drugs, or their respective placebos. The primary outcome was 90-day all-cause mortality. Secondary outcomes included mortality at intensive care unit (ICU) discharge and hospital discharge and at day 28 and day 180 and the number of days alive and free of vasopressors, mechanical ventilation, or organ failure. After drotrecogin alfa (activated) was withdrawn from the market, the trial continued with a two-group parallel design. The analysis compared patients who received hydrocortisone plus fludrocortisone with those who did not (placebo group). RESULTS: Among the 1241 patients included in the trial, the 90-day mortality was 43.0% (264 of 614 patients) in the hydrocortisone-plus-fludrocortisone group and 49.1% (308 of 627 patients) in the placebo group (P=0.03). The relative risk of death in the hydrocortisone-plus-fludrocortisone group was 0.88 (95% confidence interval, 0.78 to 0.99). Mortality was significantly lower in the hydrocortisone-plus-fludrocortisone group than in the placebo group at ICU discharge (35.4% vs. 41.0%, P=0.04), hospital discharge (39.0% vs. 45.3%, P=0.02), and day 180 (46.6% vs. 52.5%, P=0.04) but not at day 28 (33.7% and 38.9%, respectively; P=0.06). The number of vasopressor-free days to day 28 was significantly higher in the hydrocortisone-plus-fludrocortisone group than in the placebo group (17 vs. 15 days, P<0.001), as was the number of organ-failure-free days (14 vs. 12 days, P=0.003). The number of ventilator-free days was similar in the two groups (11 days in the hydrocortisone-plus-fludrocortisone group and 10 in the placebo group, P=0.07). The rate of serious adverse events did not differ significantly between the two groups, but hyperglycemia was more common in hydrocortisone-plus-fludrocortisone group. CONCLUSIONS: In this trial involving patients with septic shock, 90-day all-cause mortality was lower among those who received hydrocortisone plus fludrocortisone than among those who received placebo. (Funded by Programme Hospitalier de Recherche Clinique 2007 of the French Ministry of Social Affairs and Health; APROCCHSS ClinicalTrials.gov number, NCT00625209 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the ADRENAL [479] study, hydrocortisone was administered for a maximum of seven days or until ICU discharge or death; in APROCCHSS [478] hydrocortisone was administered for seven days; in VANISH [354] 200 mg of hydrocortisone was administered daily for 5 days and then tapered over further 6 days.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [478]
In the citing paper
“In APROCCHSS [478] the dose of vasopressor was ≥ 0.25 µg/kg/min or ≥ 1 mg/h of norepinephrine or epinephrine, or any other vasopressor for at least 6 h to maintain a MAP ≥ 65 mmHg.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [478]
In the citing paper
“Since then, three large RCTs have been published [354, 478, 479].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [478]
Citations
Cites
The third international consensus definitions for sepsis and septic shock (Sepsis-3).
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J.-D., Coopersmith, C. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0287 · Cited by 28,250
Self-citationDellinger, R. P., Levy, M. M., Carlet, J. M., Bion, J., Parker, M. M., Jaeschke, R., Reinhart, K., Angus, D. C., Brun-Buisson, C., Beale, R., et al. (2008) · Intensive Care Medicine · doi:10.1007/s00134-007-0934-2 · Cited by 6,772
Self-citationSurviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
Self-citationVincent, J.-L., de Mendonca, A., Cantraine, F., Moreno, R., Takala, J., Suter, P. M., Sprung, C. L., Colardyn, F., & Blecher, S. (1998) · Critical Care Medicine · doi:10.1097/00003246-199811000-00016 · Cited by 3,463
Annane, D. (2002) · JAMA · doi:10.1001/jama.288.7.862 · Cited by 3,087
Self-citationShankar-Hari, M., Phillips, G. S., Levy, M. L., Seymour, C. W., Liu, V. X., Deutschman, C. S., Angus, D. C., Rubenfeld, G. D., Singer, M., & for the Sepsis Definitions Task Force (2016) · JAMA · doi:10.1001/jama.2016.0289 · Cited by 2,424
Hydrocortisone Therapy for Patients with Septic Shock
Sprung, C. L., Annane, D., Keh, D., Moreno, R., Singer, M., Freivogel, K., Weiss, Y. G., Benbenishty, J., Kalenka, A., Forst, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa071366 · Cited by 2,132
Self-citationAnnane, D., Bellissant, E., & Cavaillon, J.-M. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17667-8 · Cited by 1,213
Self-citationAnnane, D., Vignon, P., Renault, A., Bollaert, P.-E., Charpentier, C., Martin, C., Troché, G., Ricard, J.-D., Nitenberg, G., Papazian, L., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61344-0 · Cited by 567
Self-citationCognitive decline after sepsis.
Annane, D., & Sharshar, T. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70246-2 · Cited by 290
Self-citation
Research works printed but not linked: 1
- Guide “100 recommandations pour la surveillance et la préventions des infections nosocomiales.” Bulletin Epidémiologique Hebdomadaire. No. 48. November 30 1992 (http://invs.santepubliquefrance.fr/beh/1992/48/index.html).
Cited by
Items 501–600 of 968
Iwasaku, M., Tanaka, S., Shinzawa, M., & Kawakami, K. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.04.001 · Cited by 7
Takubo, M., Tanaka, S., Kushimoto, M., Ikeda, J., Ogawa, K., Suzuki, Y., Abe, M., Ishihara, H., & Fujishiro, M. (2020) · Antibiotics · doi:10.3390/antibiotics9040201 · Cited by 7
New York State Infection Control
Habboush, Y. Y., Benham, M. D., Louie, T., Noor, A., & Sprague, R. M. (2020) · StatPearls · Cited by 6
Estrategia integral de reanimación del paciente con sepsis y shock séptico
del Río-Carbajo, L., Olmo, J. N.-D., Fernández‐Ugidos, P., & Vidal, P. (2022) · Medicina Intensiva · doi:10.1016/j.medin.2022.02.003 · Cited by 9
Running from a Bear: How We Teach Vasopressors, Adrenoreceptors, and Shock
Manson, D. K., Dzierba, A. L., Seitz, K. M., & Brodie, D. (2023) · ATS Scholar · doi:10.34197/ats-scholar.2021-0132ht · Cited by 6
Toward Increased Understanding of the Steroid Controversy in Septic Shock
Russell, J. A., & Sevransky, J. (2019) · Critical Care Medicine · doi:10.1097/ccm.0000000000004038 · Cited by 6
Annane, D., Pirracchio, R., Billot, L., Waschka, A. K., Chevret, S., Cohen, J., Finfer, S. R., Gordon, A. C., Hammond, N. E., Myburgh, J., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-040931 · Cited by 6
Self-citationThe Evolving Understanding of Glucocorticoid Treatment in Septic Shock
Hibbert, K. A. (2023) · NEJM Evidence · doi:10.1056/evide2300105 · Cited by 7
Wu, J., Liu, M., Liu, T., Huang, P., Restinia, M., Hsu, W., Tsai, Y., Chuang, M., Hung, K., & Lai, C. (2024) · Infection · doi:10.1007/s15010-024-02381-z · Cited by 13
Research trends and hotspots on septic shock: a bibliometric study and visualization analysis
Wang, S., Li, N., Ma, B., Zhu, S., Zhou, Y., & Ma, R. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1490462 · Cited by 5
Vignon, P., Léger, J., Evrard, B., Goudelin, M., Vaidie, J., Brit, S., & Giraudeau, B. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-101200 · Cited by 5
Chang, W.-H., Hu, T.-Y., & Kuo, L. (2025) · Life · doi:10.3390/life15081317 · Cited by 5
“Recent meta-analyses—including those by Chang et al., Fujii et al., and Suzuki et al.—further support the notion that any mortality benefit is limited to high-risk subgroups with early therapy and elevated endotoxin levels [10,11,20,24].”
Mortality in the Sepsis-3 Era: A Systematic Review of Multicenter Randomized Controlled Trials
Nemet, M., Karakuş, İ. S., Gmehlin, C. G., Halpern, G. A., Ghafouri, K., Abramovich, S., Raghu, R., Pastrak, M., Nikravangolsefid, N., Gerberi, D., et al. (2025) · Shock · doi:10.1097/shk.0000000000002687 · Cited by 6
Corticosteroids in bacterial severe community-acquired pneumonia: lessons from recent trials
Nguyen, T. L., Duong, H. N. T., Tran, C. D., Pham, P. T., Ho, V. H., & Duong, V. P. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1718570 · Cited by 5
Chang, W.-H., Yang, S.-H., Shen, H.-F., Hu, T.-Y., & Wu, W.-J. (2025) · Biomedicines · doi:10.3390/biomedicines13122904 · Cited by 5
“For example, prolonged low-dose corticosteroid therapy did not significantly reduce mortality in large septic shock trials [18,19]; resuscitation guided by peripheral perfusion targets (capillary refill time) conferred no survival advantage over lactate-guided resuscitation [20]; and the novel…”
Li, J., Zhang, Y., Jiang, F., Shi, X., Tu, M., Liu, Z., & Ye, F. (2026) · Inflammation Research · doi:10.1007/s00011-025-02173-7 · Cited by 5
“The APROCCHSS study also explored the combination of hydrocortisone with fludrocortisone [ 4 ].”
Badero, O. J., Omokore, O. A., Oore-ofe, O., Osibowale, B. T., Quadri, I. O., Olayinka, T. O., Olabode, D., Kalu, K. E., Adeyemi, A., Buari, M. O., et al. (2026) · Cureus · doi:10.7759/cureus.106312 · Cited by 6
How Would You Treat This Patient Hospitalized With Community-Acquired Pneumonia?
Kanjee, Z., Metlay, J. P., Moskowitz, A. L., & Reynolds, E. E. (2021) · Annals of Internal Medicine · doi:10.7326/m21-3650 · Cited by 5
Deshpande, S. R., Bearl, D. W., Eghtesady, P., Henderson, H., Auerbach, S. R., Jeewa, A., Bansal, N., Amdani, S. M., Richmond, M. E., Sacks, L. D., et al. (2022) · Pediatric Transplantation · doi:10.1111/petr.14392 · Cited by 5
Institution-free days after critical illness: A multicenter retrospective study
Marella, P., Laupland, K. B., Shekar, K., Tabah, A., Edwards, F., & Ramanan, M. (2023) · Journal of Critical Care · doi:10.1016/j.jcrc.2023.154253 · Cited by 5
Fighting sepsis: still a long way to go
Machado, F. R., Zampieri, F. G., & Myatra, S. N. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00006-1 · Cited by 5
Cheng, X., Fu, Z., Liu, Y., Zheng, X., & Hu, T. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1190758 · Cited by 11
“(8) reported that 90-day all-cause mortality was lower in septic patients treated with hydrocortisone (50-mg intravenous bolus every 6 h) plus fludrocortisone (50-micro g tablet once daily) for 7 days compared with placebo (the Activated Protein C and Corticosteroids for Human Septic Shock trial, abbreviated as the AP…”
BackgroundMethodAdjunctive Therapies in Acute Respiratory Distress Syndrome
Trieu, M., & Qadir, N. (2023) · Critical Care Clinics · doi:10.1016/j.ccc.2023.12.004 · Cited by 6
Fang, D., Chabrier-Rosello, J. O., McMahon, B. A., Fülöp, T., & Achanti, A. (2019) · ASAIO Journal · doi:10.1097/mat.0000000000001100 · Cited by 5
Severe Sepsis: The Fragile Anatomy of Crude Mortality
Vissichelli, N. C., Sima, A. P., & Wenzel, R. P. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab677 · Cited by 5
Liu, H., Hu, J., Xiao, J., Kang, H., & Zhou, F. (2022) · World Journal of Emergency Medicine · doi:10.5847/wjem.j.1920-8642.2022.095 · Cited by 5
Should We Add Fludrocortisone to Hydrocortisone for Treatment of Septic Shock?
Matthay, M. A., Dahabreh, I. J., & Thompson, B. (2023) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.0257 · Cited by 5
Lock, A. E., Gutierrez, G., Hand, E., Barthol, C. A., & Attridge, R. L. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231164210 · Cited by 5
“10 Other aspects of sepsis management remained consistent during the study period and were not considered to have significantly affected study definitions or data collection.”
BackgroundMethodInfluentialTyagi, A., Salhotra, R., Sharahudeen, A., Rautela, R. S., & Kemprai, R. (2024) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-24793 · Cited by 5
Was ist gesichert in der Therapie der Sepsis?
Stahl, K., Seeliger, B., David, S., & Schmidt, J. J. (2020) · Der Internist · doi:10.1007/s00108-020-00895-w · Cited by 7
Wu, Y., & Lauffenburger, J. C. (2020) · PLoS ONE · doi:10.1371/journal.pone.0243149 · Cited by 7
“Another large RCT, APROCCHSS [12], however, reported that mortality was significantly lower at hospital discharge in the corticosteroid group (39.”
BackgroundResultInfluentialA Novel Human Glucocorticoid Receptor Variant, G459V, is Hyperactive in Response to Steroids
Grigsby, M. J., Green, T. L., Lim, D., Cho, K., & Greenhalgh, D. G. (2021) · Shock · doi:10.1097/shk.0000000000001729 · Cited by 5
Role of steroids in critically-ill sepsis patients: a review article and literature to review
Mirza, M. M., Zafar, M., Siddiqui, M., Abbas, A., Nahas, J., Mirza, M., & Tauseef, A. (2021) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2021.1964164 · Cited by 6
When and how to use predictive biomarkers for corticosteroid treatment of septic shock
Russell, J. A. (2018) · Critical Care · doi:10.1186/s13054-018-2254-z · Cited by 5
Lemieux, S. M., Levine, A. R., & Gritsenko, D. (2019) · Critical Care Medicine · doi:10.1097/ccm.0000000000003980 · Cited by 5
Fludrocortisone with hydrocortisone in sepsis: new evidence in an ongoing debate
Ranzani, O., Annane, D., & Singer, M. (2024) · Intensive Care Medicine · doi:10.1007/s00134-024-07699-8 · Cited by 5
“In the APROCCHSS trial enrolling 1241 patients with septic shock, there was a reduction in 90-day mortality in those who received hydrocortisone plus fludrocorti-sone 50 µg orally compared with placebo, and this was associated with more vasopressor-and organ failure-free days [7].”
Self-citationDorin, R. I., Urban, F. K., Perogamvros, I., & Qualls, C. R. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac173 · Cited by 4
Mortality time frame variability in septic shock clinical trials: A systematic review
Laserna, A., Cuenca, J. A., Martin, P., Fowler, C., Correa, J. E. B., Manjappachar, N. K., Fowler, C. S., Lopez-Olivo, M. A., Borges, M., Sprung, C. L., et al. (2025) · Medicina Intensiva · doi:10.1016/j.medine.2025.502172 · Cited by 7
Bastida, C., Lugea, A. E., Fernández-Polo, A., Moreno, F. B., Cerezuela, M. M., Chiva, E. D., García, T. B., García, M. Á. A., González, I., Albanell‐Fernández, M., et al. (2025) · Farmacia Hospitalaria · doi:10.1016/j.farma.2025.05.009 · Cited by 5
Bench-to-Bedside Insights into the Challenges of Immunosuppression in Sepsis
Huang, S., Huang, S., Huang, X., Feng, X., Wang, R., Liu, D., Sun, J., Zhang, H., Du, J., Lin, L., et al. (2026) · Pathogens · doi:10.3390/pathogens15020159 · Cited by 6
“…with control treatment, treatment with glucocorticoids can shorten the time to shock reversal, duration of first mechanical ventilation, ICU length of stay, and transfusion requirements in patients with septic shock without significantly increasing the incidence of secondary infections [62,63].”
Li, Z., Zhang, X., Wu, Y., Xie, C., Liu, C., He, X., Wu, Z., Hua, G., & Li, Y. (2023) · Emergency and Critical Care Medicine · doi:10.1097/ec9.0000000000000072 · Cited by 4
Aspek Farmakologi dan Indikasi Corticosteroid
Setiawan, G., & Suardamana, K. (2023) · Cermin Dunia Kedokteran · doi:10.55175/cdk.v50i11.623 · Cited by 4
TR4 worsen urosepsis by regulating GSDMD
Wang, H., Zhu, S., Zhou, Z., Wang, Z., Zhuang, W., Xue, D., Lu, Z., Zheng, Q., Ding, L., Ren, L., et al. (2024) · European journal of medical research · doi:10.1186/s40001-024-01742-6 · Cited by 4
“Notably, controlling cytokine storms has been proven to improve the prognosis of patients with sepsis [14, 15].”
BackgroundSafety of steroids in severe community-acquired pneumonia
Piedepalumbo, F. V., Motos, A., Blasi, F., & Torres, A. (2025) · European Respiratory Review · doi:10.1183/16000617.0131-2024 · Cited by 6
Xu, J., Cai, H., & Zheng, X. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-10731-x · Cited by 4
DeMasi, S. C., Imhoff, B., Lewis, A. A., Seitz, K. P., Driver, B. E., Gibbs, K. W., Ginde, A. A., Trent, S. A., Russell, D. W., Muhs, A. L., et al. (2025) · CHEST Critical Care · doi:10.1016/j.chstcc.2025.100177 · Cited by 4
Zhu, X., Xue, J., Maimaitituerxun, R., Liu, Y., Zhou, Q., Zhou, Q., Zhao, S., Xu, H., Xie, H. W., Dai, W., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-05515-x · Cited by 4
“Further subgroup analyses revealed that hydrocortisone use was linked to higher mortality, whereas dexamethasone showed a trend toward a protective effect, although the association was not statistically significant (in-hospital mortality: HR 0.70 [0.41–1.18]; ICU mortality: HR 0.69 [0.37–1.29]).”
InfluentialThe Role of SR-BI in sepsis: leveraging mechanistic insights to advance precision steroid therapy
Guo, L., Wang, Q., & Li, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1643395 · Cited by 4
Kulesza, S., Gignac, L., Colvin, C. A., Boll, S., Giuliano, C. A., Haan, B. J., Allen, B., Perez, M. M., Allen, M., & Edwin, S. B. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2811 · Cited by 4
“8 12 The SSC guidelines suggest that corticosteroids should be initiated at a norepinephrine-equivalent dose greater than or equal to 0.25 mcg/kg/min at least 4 h following vasopressor initiation.”
BackgroundInfluentialLiu, L., Huang, S., Chen, Z., Chen, L., Li, Z., Lin, X., Zhu, J., Wang, S., Tan, Y., & Chen, X. (2024) · Geriatric Nursing · doi:10.1016/j.gerinurse.2024.08.036 · Cited by 4
An overview of the recent trials of corticosteroids for severe community-acquired pneumonia
Edland, B., & WATERER, G. W. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2513518 · Cited by 4
“The primary APROCCHSS study found a survival benefit in favor of the combination of hydrocortisone (50mcg qid for 7 days) plus fludrocortisone (50mcg daily for 7 days) in patients with severe sepsis [14].”
Complications Associated with Glucocorticoids Treatment in Critically Ill Patients
Confalonieri, P., Reccardini, N., Kette, S., & Salton, F. (2025) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2661-5208 · Cited by 4
McDonnell, E., Collins, R. D., Hernández, M., & Brown, A. R. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220910788 · Cited by 4
“Organ failure recovery was defined as a decrease in sequential organ failure assessment (SOFA) score to less than 6.(2) Hyperglycemia was defined as two consecutive blood glucose values 150mg/dL during the first seven days of septic shock.”
BackgroundMethodResultInfluentialThe Role of Vagus Nerve Stimulation in Sepsis
Asad, Z. U. A., Przebinda, A. S., Chaudhary, A. M. D., Farooqui, S. M., Youness, H. A., & Stavrakis, S. (2020) · Bioelectronics in Medicine · doi:10.2217/bem-2020-0010 · Cited by 5
Critical care essentials for pharmacy trainees and new clinical practitioners
Erstad, B. L., Kiser, T. H., & Bauer, S. R. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa417 · Cited by 4
Efficacy and safety of corticosteroids in immunocompetent patients with septic shock
Lu, X., Han, W., Gao, Y., Guo, S., Yu, S., Yu, X., Zhu, H., & Li, Y. W. (2021) · World Journal of Emergency Medicine · doi:10.5847/wjem.j.1920-8642.2021.02.007 · Cited by 6
Frenkel, A., Abuhasira, R., Bichovsky, Y., Bukhin, A., Novack, V., Brotfain, E., Zlotnik, A. A., & Klein, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-85172-y · Cited by 4
Huang, C., Miles, T. J., Thomas, B., Todd, S., Wilson, C. T., & Suliburk, J. W. (2021) · Injury · doi:10.1016/j.injury.2021.05.036 · Cited by 4
Immunomodulator use in paediatric severe sepsis and septic shock
Lee, A. O. C. J., Chua, A. H. Y., Sultana, R., Lee, J. H., & Wong, J. J. (2021) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.2021178 · Cited by 4
Sepsis and Septic Shock: Evolving Evidence, Evolving Paradigms
Shorr, A. F., & Zilberberg, M. D. (2022) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0041-1740975 · Cited by 5
Lenney, M., Kopp, B. J., & Erstad, B. L. (2022) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxac156 · Cited by 4
Dargent, A., Bourredjem, A., Argaud, L., Lévy, B., Fournel, I., Cransac, A., Badie, J. C., Quintin, L., & Quenot, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.968274 · Cited by 4
“Corticosteroids Corticosteroid replacement therapy will be prescribed, with the combination of hydrocortisone (200 mg/24 h) and fludrocortisone (50 μg tablet once a day) (30).”
BackgroundSelf-citationSeptic Shock and Cardiac Arrest in Obstetrics
Pacheco, L. D., Shepherd, M. C., & Saade, G. S. (2022) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2022.02.002 · Cited by 5
Kanjee, Z., Berg, K. M., Bell, T. D., & Reynolds, E. E. (2023) · Annals of Internal Medicine · doi:10.7326/m22-3385 · Cited by 4
Li, M., Noordam, R., Winter, E. M., van Meurs, M., Bouma, H. R., Arbous, M. S., Rensen, P. C. N., & Kooijman, S. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115961 · Cited by 6
“Consequently, clinical trials with short-and long-term mortality as primary outcome have shown either benefit or no clear impact [10 – 12].”
Goder, N., Gerstenhaber, F., Gal‐Oz, A., Stavi, D., Angel, Y., Nini, A., Lichter, Y., & Sold, O. (2024) · Critical Care Explorations · doi:10.1097/cce.0000000000001086 · Cited by 6
Hollow adrenal gland sign on dual-phase contrast-enhanced CT in critically ill patients with sepsis
Park, J. E., Lee, G. T., Lee, J., Kim, Y. M., Shin, T. G., Lee, S. U., Kim, T., Yoon, H. J., Cha, W. C., & Hwang, S. Y. (2020) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2020.10.046 · Cited by 11
Corticosteroids in Adult Cardiac Surgery—Yet Another Paper
Patvardhan, C., & Vuylsteke, A. (2018) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2018.05.009 · Cited by 4
Vornicu, O., Perriens, E., Blackman, S., Smoos, E., Al-Sammour, C., Oueslati, I., Philippot, A., Bankier, D. V., Haddad, C., Bendoumou, M., et al. (2023) · Annals of Translational Medicine · doi:10.21037/atm-23-1719 · Cited by 4
Torbic, H., Bulgarelli, L., Deliberato, R. O., & Duggal, A. (2023) · Journal of Pharmacy Practice · doi:10.1177/08971900231185392 · Cited by 3
Aldhaeefi, M., Alshaya, A. I., Belrhiti, S., & Rungkitwattanakul, D. “. (2023) · Critical Care Explorations · doi:10.1097/cce.0000000000000940 · Cited by 4
Vinnat, V., Annane, D., & Chevret, S. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13111560 · Cited by 4
Self-citationOu, S., Hsu, Y.-C., Fu, S., Lin, L., & Lin, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316572 · Cited by 3
“The three-month mortality rate among patients with septic shock is nearly 50% [1].”
BackgroundWu, W., Zhang, Y., Qu, X., Zhang, C., & Zhang, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-77842-4 · Cited by 3
Host-Directed Adjunctive Therapies in Immunocompromised Patients with Pneumonia
Hensley, M. K., & Cruz, C. S. D. (2024) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2024.10.003 · Cited by 3
Immunopharmacological Insights into Cordyceps spp.: Harnessing Therapeutic Potential for Sepsis
Saxena, J., Agarwal, G., Das, S., Kumar, A., Thakkar, K., Kaushik, S., Srivatsava, V. K., Siddiqui, A. J., & Jyoti, A. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128326301240920040036 · Cited by 3
Reinert, J. P., Becker, K., & Ohlinger, M. J. (2025) · Journal of Pharmacy Technology · doi:10.1177/87551225251320873 · Cited by 3
Redrawing the map for corticosteroids in severe community-acquired pneumonia
WATERER, G. W., & Rello, J. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.07.001 · Cited by 3
Mahmoudi, P. S., Sadeghi, F., Saberian, M., Khalili, H., & Shafaati, M. (2026) · Journal of Anesthesia Analgesia and Critical Care · doi:10.1186/s44158-025-00335-x · Cited by 3
HDAC1 modulates sepsis-induced immunosuppression by driving the exhaustion of CD8+ T cells
Liu, D., Fan, J.-B., Wang, R., Li, Y., Bi, W.-D., Huang, S.-Y., Nie, H.-H., Feng, X.-F., Zhang, H.-C., Du, J., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.197224 · Cited by 3
Current status of immunomodulatory therapies in adult sepsis patients: where do we stand?
Papatheodosiou, D., Giamarellos‐Bourboulis, E. J., & Tsoukas, C. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2646192 · Cited by 3
“Two trials assessing hydrocortisone + SoC as opposed to hydrocortisone + fludrocortisone + SoC (adjunctive corticosteroid treatment in patients with septic shock (ADRENAL study) and activated protein C and corticosteroids for human septic shock (APROCCHSS study)) yielded conflicting results [57,58].”
International multidisciplinary consensus statement on sepsis code guidelines: A Delphi approach
Borges-Sa, M., Giglio, A., Martín‐Loeches, I., Nates, J., del Castillo, J. G., Cardenas, Y., Mergulhão, P., Candel, F. J., Zaragoza, R., Escartín, M. N. L., et al. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70145 · Cited by 4
Optimization of Pharmacist Medication Management and Mortality in the ICU
Smith, S. E., Keats, K. R., Heavner, M. S., Chen, Z., Chen, X., Devlin, J. W., Murphy, D. J., Martin, G. S., Burden, M. A., Murray, B., et al. (2026) · CHEST Journal · doi:10.1016/j.chest.2026.09.027 · Cited by 3
Wu, J., Huang, M., Wang, Q., Ma, Y., & Jiang, L. (2019) · Hong Kong Journal of Emergency Medicine · doi:10.1177/1024907919833205 · Cited by 4
John, K. E., Kirkpatrick, M., Aytoda, P., Elefritz, J. L., Palettas, M. S., Rosales, B. N., Murphy, C. V., & Doepker, B. A. (2024) · International Journal of Critical Illness and Injury Science · doi:10.4103/ijciis.ijciis_66_23 · Cited by 3
“[8] Additional studies have investigated the role of steroids in septic shock and found similar results; however, these trials did not include fludrocortisone.”
InfluentialMineralocorticoid Receptor and Sleep Quality in Chronic Kidney Disease
de la Puente-Aldea, J., Lopez-Llanos, O., Horrillo, D., Marcos-Sánchez, H., Sanz-Ballesteros, S., Franco, R., Jaisser, F., Senovilla, L., & Palacios, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212320 · Cited by 4
Methylene Blue in Septic Shock: Emerging Evidence, Clinical Applications, and Future Directions
Maheshwari, N., Malkania, B., & Mudiyanselage, R. (2025) · Cureus · doi:10.7759/cureus.86701 · Cited by 3
Critical illness-related corticosteroid insufficiency: What we know and what we don’t know
Rivas, M., & Sotello, D. (2019) · The Southwest Respiratory and Critical Care Chronicles · doi:10.12746/swrccc.v7i31.595 · Cited by 3
“A recent study in which a 7-day treatment with a 50-mg intravenous bolus of hydrocortisone every 6 hours and a daily dose of 50 μg of oral fludrocortisone resulted in lower mortality at day 90 and ICU and hospital discharge than placebo among adults with septic shock.(22) The Surviving Sepsis Guidelines recommend usin…”
BackgroundRelações da corticoterapia no tratamento do choque séptico
Neta, A. B. C. S., Chaves, A. C. H., Dias, L. R., Mascarenhas, I. R., Macêdo, I. M., Guizzetti, M. I. A., Lacerda, T. F., & Machado, L. C. D. S. (2020) · Brazilian Journal of Health Review · doi:10.34119/bjhrv3n1-101 · Cited by 3
Effect of Very Low-Dose Hydrocortisone on Shock Reversal in Patients With Septic Shock
Sbertoli, R., Hu, Z., Henke, J., Wu, E., Santosh, S., Osmon, S., Charbek, E., Jamkhana, Z. A., & Santosh, S. (2020) · Critical Care Explorations · doi:10.1097/cce.0000000000000096 · Cited by 4
Meduri, G. U., & Chrousos, G. P. (2020) · Vide Leaf, Hyderabad eBooks · doi:10.37247/paendo.1.2020.10 · Cited by 3
Mady, A. M., Abdulrahman, B., Ramadan, O. E., Mumtaz, S., Al-Odat, M. A., Kuhail, A., Altoraifi, R., Alshae, R., Harthy, A. M. A., Καρακίτσος, Δ., et al. (2022) · Heart & Lung · doi:10.1016/j.hrtlng.2022.06.024 · Cited by 3
Montero, V. R., Ribes, C. M., Montell, M. P., & Zaragoza, R. (2022) · Medicina Intensiva · doi:10.1016/j.medin.2022.03.005 · Cited by 3
Early Clinical Management of Sepsis: Past, Present, and Future
Anyalebechi, J. C., & Coopersmith, C. M. (2022) · Journal of Translational Critical Care Medicine · doi:10.4103/jtccm-d-22-00016 · Cited by 4
Case 37-2022: A 55-Year-Old Man with Fatigue, Weight Loss, and Pulmonary Nodules
Roberts, M. B., Lee, J., Murphy, M. C., Kim, A. Y., Coglianese, E. E., & Hilburn, C. F. (2022) · New England Journal of Medicine · doi:10.1056/nejmcpc2211357 · Cited by 3
Iwasaki, N., Sekino, M., Tominaga, T., Tanaka, T., Araki, H., Yano, R., Matsumoto, S., Ichinomiya, T., Higashijima, U., Nonaka, T., et al. (2023) · Medicine · doi:10.1097/md.0000000000034680 · Cited by 4
“The mortality rate for septic shock is approximately 40%,[22,23] and Kaplan–Meier curves show that this rate is reached relatively slowly over 30 days.[24] The mortality rate of patients with STSS is also 40%,[1,2] although most deaths occur within a few days of onset, with a few patients dying after the fifth day.”
BackgroundQuigley, N. C., Binnie, A., Baig, N., Opgenorth, D. L., Senaratne, J. M., Sligl, W., Zuege, D. J., Rewa, O. G., Bagshaw, S. M., Tsang, J. L. Y., et al. (2023) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-023-02669-y · Cited by 3
Profound Vasoplegia after Coronary Artery Bypass Grafting
Chatterjee, S. (2022) · Journal of shock & hemodynamics · doi:10.57905/josh/e2022129 · Cited by 3
Miao, S., Yang, M., Li, W., Yang, Z., & Yan, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1394553 · Cited by 3
Tao, T., Shi, Y., Ye, X., Mi, W., & Lou, J. (2025) · Health Science Reports · doi:10.1002/hsr2.70360 · Cited by 3
“Such disparities may stem from variations in study design and patient heterogeneity (including infection site, etiology, comorbidity, etc) [11].”
Metadata
- Authors
- Annane, D., Renault, A., Brun-Buisson, C., Megarbane, B., Quenot, J.-P., Siami, S., Cariou, A., Forceville, X., Schwebel, C., Martin, C., Timsit, J.-F., Misset, B., Ali Benali, M., Colin, G., Souweine, B., Asehnoune, K., Mercier, E., Chimot, L., Charpentier, C., François, B., Boulain, T., Petitpas, F., Constantin, J.-M., Dhonneur, G., Baudin, F., Combes, A., Bohé, J., Loriferne, J.-F., Amathieu, R., Cook, F., Slama, M., Leroy, O., Capellier, G., Dargent, A., Hissem, T., Maxime, V., & Bellissant, E.
- Affiliations
- Inserm (FR)
- From Service de Médecine Intensive et Réanimation, Hôpital Raymond Poincaré, Garches (D.A., V.M.), Laboratory of Infection and Inflammation Unité 1173, University of Versailles Saint-Quentin-en-Yvelines, INSERM, Montigny-le-Bretonneux (D.A.), Service de Pharmacologie Clinique–Centre d’Investigation Clinique (CIC) INSERM 1414, Centre Hospitalier Universitaire (CHU) de Rennes–Université de Rennes 1, Hôpital Pontchaillou, Rennes (A.R., E.B.), Service de Réanimation Médicale (C.B.-B.) and Service...
- ORCID
- Annane, Djillali
- Renault, Alain
- Quenot, Jean-Pierre
- Siami, Shidasp
- Cariou, Alain
- Forceville, Xavier
- Schwebel, Carole
- Misset, Benoît
- Souweine, Bertrand
- Asehnoune, Karim
- François, Bruno
- Boulain, Thierry
- Constantin, Jean-Michel
- Combes, Alain
- Bohé, Julien
- Amathieu, Roland
- Cook, Fabrice
- Slama, Michel
- Capellier, Gilles
- Dargent, Auguste
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-03
- Volume
- 378
- Issue
- 9
- Pages
- 809-818
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2794125559
- Cited by
- 939
- References
- 22
- Citations by year
- 2026: 107 · 2025: 104 · 2024: 97 · 2023: 115 · 2022: 101 · 2021: 98 · 2020: 121 · 2019: 123 · 2018: 70
- FWCI
- 80.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Funders
- Ministère des Affaires Sociales et de la Santé (Programme Hospitalier de Recherche Clinique / P 07)
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Keywords
- cortisol, fludrocortisone, drotrecogin alfa (activated), corticosteroid therapy, host response to infection, 90-day mortality, vasopressor-free days, organ failure, mechanical ventilation, intensive care unit discharge, sepsis treatment
- MeSH terms
- Simplified Acute Physiology Score, Aged, Anti-Inflammatory Agents, Cause of Death, Combined Modality Therapy, Double-Blind Method, Drug Therapy, Combination, Female, Fludrocortisone, Humans, Hydrocortisone, Male, Middle Aged, Recurrence, Respiration, Artificial, Shock, Septic, Survival Analysis, Treatment Outcome, Renal Replacement Therapy, Organ Dysfunction Scores
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.